CSIMarket
 
Valneva Se  (NASDAQ: VALN)
 

Valneva Se's Customers Performance

VALN



 
VALN's Source of Revenues During the corresponding time, Valneva Se recorded a revenue increase by 3 % year on year, While revenue at the Valneva Se's corporate clients

List of VALN Customers




for the same period Valneva Se recorded revenue increase by 3 % year on year,

List of VALN Customers

Valneva Se's Business Units
IXIARO    56.35 % of total Revenue
DUKORAL    18.27 % of total Revenue
Third party products    10.97 % of total Revenue
IXCHIQ    4.82 % of total Revenue
Royalties received    1.22 % of total Revenue
Revenues from shipping and handling    0.28 % of total Revenue
R D work and additional support services    5.72 % of total Revenue
Milestone payment - licenses    1.96 % of total Revenue
Other services    0.05 % of total Revenue
Direct product sales    74.86 % of total Revenue
Indirect product sales    15.55 % of total Revenue
United States    30.69 % of total Revenue
Canada    17.25 % of total Revenue
Germany    10 % of total Revenue
France    8.4 % of total Revenue
Nordics    7.96 % of total Revenue
Other Europe    7.95 % of total Revenue
United Kingdom    7.24 % of total Revenue
Austria    5.42 % of total Revenue
Rest of World    5.09 % of total Revenue






Valneva Se's Comment on Sales, Marketing and Customers



The company operates in the biopharmaceutical market and collaborates with other biopharmaceutical firms for the marketing, distribution, and development of its products and product candidates. It had agreements with the Serum Institute of India (SII) concerning the manufacturing and distribution of IXCHIQ in Asia; these agreements were mutually terminated as of December 31, 2025, impacting supply in the Asian market. The company also collaborated with Bavarian Nordic for vaccine distribution in certain countries; however, these agreements were terminated following Bavarian Nordic's acquisition of another cholera vaccine. The company relies on single-source suppliers for critical materials used in manufacturing IXIARO and certain vaccine candidates, which affects its capacity to meet customer demand and launch new products.





Valneva Se’s Comment on Sales, Marketing and Customers


The company operates in the biopharmaceutical market and collaborates with other biopharmaceutical firms for the marketing, distribution, and development of its products and product candidates. It had agreements with the Serum Institute of India (SII) concerning the manufacturing and distribution of IXCHIQ in Asia; these agreements were mutually terminated as of December 31, 2025, impacting supply in the Asian market. The company also collaborated with Bavarian Nordic for vaccine distribution in certain countries; however, these agreements were terminated following Bavarian Nordic's acquisition of another cholera vaccine. The company relies on single-source suppliers for critical materials used in manufacturing IXIARO and certain vaccine candidates, which affects its capacity to meet customer demand and launch new products.








VALN's vs. Customers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)



COMPANY NAME MARKET CAP REVENUES INCOME EMPLOYEES
Valneva Se 0.00 195.62 -129.02 140
SUBTOTAL 0.00 0.00 0.00 -

Sources: Valneva Se’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Valneva Se’s corporate clients.
For your research, we’ve provided 9 tables on Valneva Se corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.